STOCK TITAN

Sagimet Biosciences (SGMT) SEC Filings, Mar-May 2026

SGMT NASDAQ

Sagimet Biosciences Inc. filings document a clinical-stage biopharmaceutical issuer with Series A common stock listed on the Nasdaq Global Market and emerging growth company status. Recent 8-K reports cover financial results, preliminary financial information, Regulation FD investor presentations, a material underwriting agreement and related capital-structure disclosures, and executive leadership changes.

The company’s proxy materials describe annual meeting voting matters, stockholder procedures, board-related items, and governance proposals. Its disclosures also track use-of-proceeds language, clinical-development updates for FASN inhibitor programs, and public-company reporting matters.

Rhea-AI Summary

Sagimet Biosciences Inc. reported a net loss of $10.7 million for the quarter ended March 31, 2026, an improvement from $18.2 million a year earlier. The smaller loss was driven by a 54% drop in research and development expense to $7.0 million as Phase 3 MASH work wound down and spending shifted toward acne programs.

General and administrative costs were stable at $4.7 million, while other income declined to $1.1 million due to lower cash balances and yields. Sagimet ended the quarter with $104.5 million in cash, cash equivalents and marketable securities and then raised about $175.0 million in an April 2026 underwritten offering, which it expects to fund operations for at least 12 months.

The company continues to advance FASN inhibitor programs: denifanstat, which met Phase 3 acne endpoints in China through its partner Ascletis, is planned to enter a U.S. Phase 3 acne trial after an IND filing in mid-2026, and TVB-3567 is in a Phase 1 acne study. Further MASH development will pause until non-dilutive financing is secured.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
quarterly report
-
Rhea-AI Summary

Sagimet Biosciences Inc. entered into an underwriting agreement for an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share. The Company expects to receive $164.5 million in net proceeds after underwriting discounts and commissions.

The Company plans to use the proceeds, together with existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, advance TVB-3567 through Phase 2 topline results, move a topical FASN inhibitor to IND submission, and for general corporate purposes including additional clinical development, working capital and operating expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.76%
Tags
current report
-
Rhea-AI Summary

Sagimet Biosciences is offering 29,166,700 shares of Series A common stock at $6.00 per share, for an aggregate offering price of $175,000,200 via a shelf prospectus supplement. The underwriters’ discount is $0.36 per share, providing estimated net proceeds to the company of approximately $163.9 million. The shares are expected to be delivered on or about April 28, 2026. Proceeds are intended to fund a Phase 3 acne trial for denifanstat, advance TVB-3567 through Phase 2 topline results, support a topical FASN program to IND, and for general corporate purposes. The supplement discloses a preliminary cash balance of approximately $104.5 million as of March 31, 2026 (unaudited).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.76%
Tags
prospectus
Rhea-AI Summary

Sagimet Biosciences Inc. furnished an updated investor slide presentation as an exhibit to a current report. The presentation, dated April 27, 2026, is attached as Exhibit 99.1 and will be used in meetings with investors.

The materials are provided under Item 7.01 as information that is being furnished, not deemed filed under the Exchange Act, and are only incorporated by reference in other filings if specifically referenced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.57%
Tags
current report
-
Rhea-AI Summary

Sagimet Biosciences Inc. furnished preliminary financial data and strategic updates. The company estimates unaudited cash, cash equivalents and marketable securities of approximately $104.5 million as of March 31, 2026, noting this figure may change after normal closing procedures and review.

Sagimet plans a U.S. Phase 3 clinical trial of its FASN inhibitor denifanstat for moderate to severe acne, expected to start in the second half of 2026, following positive Phase 3 safety data from its license partner in China. A first-in-human Phase 1 trial of FASN inhibitor TVB-3567 is ongoing.

The company is prioritizing its dermatology franchise in capital allocation and plans to advance its MASH program only if it secures non-dilutive funding. Sagimet will host a virtual KOL event on April 30, 2026 at 2 p.m. ET to discuss denifanstat’s acne development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.57%
Tags
current report
-
ARS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
annual report
Rhea-AI Summary

Sagimet Biosciences Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 12, 2026 at 9:30 a.m. Pacific Time. Stockholders of record as of April 17, 2026, holding 32,017,613 shares of Series A common stock, may vote online, by phone, mail or during the meeting.

Investors will elect four Class III directors—Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D.—to three-year terms ending in 2029, and ratify KPMG LLP as independent auditor for 2026. The eight-member Board includes six independent directors and uses annual self-evaluations, fully independent committees and a lead independent director structure.

The company highlights recent progress, including China partner Ascletis’ positive Phase 3 acne results and NMPA acceptance of a denifanstat NDA, initiation of a Phase 1 trial for TVB‑3567, and establishment of a $75.0 million at-the-market program for Series A common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
proxy
-
Rhea-AI Summary

Sagimet Biosciences Inc. reported a leadership transition in its clinical organization. On April 20, 2026, Chief Medical Officer Eduardo Martins, M.D., D.Phil. retired from his officer role and will continue supporting the company as an external scientific advisor.

The company simultaneously appointed Andreas Grauer, M.D. as its new Chief Medical Officer, effective the same date. Dr. Grauer brings prior CMO experience at several biopharmaceutical companies and a long tenure in drug development roles, while maintaining an academic appointment at the University of Heidelberg Medical School.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.23%
Tags
current report
-
Rhea-AI Summary

Sagimet Biosciences reported 2025 results and outlined progress across its MASH, acne and oncology programs. For 2025, total operating expenses were $56.9 million and net loss was $51.0 million, compared with a $45.6 million net loss in 2024. Fourth-quarter 2025 net loss was $9.6 million versus $16.2 million a year earlier. Cash, cash equivalents and marketable securities were $113.1 million as of December 31, 2025, which the company expects will fund operations through the third quarter of 2027.

Clinically, denifanstat continued to show strong Phase 2b data in MASH, including statistically significant improvements in steatohepatitis and fibrosis, and positive safety. A Phase 1 pharmacokinetic trial of a denifanstat/resmetirom combination was completed, with a Phase 2 trial in MASH cirrhosis (F4) planned for the second half of 2026. In acne, partner Ascletis’ Phase 3 trial of denifanstat met all primary and secondary endpoints, and China’s regulator accepted an NDA for moderate to severe acne in 2025.

Sagimet also highlighted its follow‑on FASN inhibitor TVB‑3567, now in a first‑in‑human Phase 1 trial for acne, and exploratory oncology work targeting FASN‑dependent tumors, supporting a multi‑indication pipeline built around FASN inhibition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.80%
Tags
current report
Rhea-AI Summary

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on fatty acid synthase (FASN) inhibitors for liver disease, acne and cancer. Its lead oral FASN inhibitor, denifanstat, achieved statistically significant Phase 2b results in MASH, improving liver fat, inflammation and fibrosis biomarkers and was generally well tolerated.

Denifanstat received FDA Breakthrough Therapy designation in October 2024 for non-cirrhotic MASH with F2–F3 fibrosis, and Sagimet has completed end-of-Phase 2 FDA interactions. A Phase 1 pharmacokinetic trial combining denifanstat with THR-β agonist resmetirom showed no safety signals, supporting a planned Phase 2 proof-of-concept trial in F4 MASH in the second half of 2026, subject to regulatory consultation.

In acne, China partner Ascletis reported that denifanstat met all primary and secondary endpoints in a 480-patient Phase 3 trial in moderate to severe acne and that the China NMPA accepted its NDA in December 2025. An open-label Phase 3 extension showed generally well-tolerated long-term use. Sagimet is also developing oral FASN inhibitor TVB-3567, now in a first-in-human Phase 1 acne study with a Phase 2 start anticipated in 2026, and is exploring oncology applications where tumors depend on FASN-driven lipid metabolism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.80%
Tags
annual report

FAQ

How many Sagimet Biosciences (SGMT) SEC filings are available on StockTitan?

StockTitan tracks 77 SEC filings for Sagimet Biosciences (SGMT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Sagimet Biosciences (SGMT)?

The most recent SEC filing for Sagimet Biosciences (SGMT) was filed on November 16, 2026.